Abstract 2256P
Background
In this study, we aimed to investigate the microenvironment of normal mucosa to predict prognosis of stage II/III colorectal cancer (CRC), after surgery.
Methods
We divide the groups using transcriptome sequencing data of prospectively collected tumors and paired normal tissue, obtained from the margins of the resected specimens from 111 patients at Samsung medical center. Groups were defined as follows: tumor-like microenvironment in normal mucosa group (tNME): high tumor signature in normal mucosa; normal microenvironment group (NME): low tumor signature in normal mucosa. The impact of this classification was further evaluated in two independent cohorts (Korean multi-center cohort and TCGA cohort). The microbial, and biological differences between groups were investigated based on 16s rRNA metagenomics and single-cell RNA sequencing.
Results
A total of 38 (34%) were classified as tNME. There were no significant differences in age, sex, TNM stage and CMS between subgroups. With a median follow-up of 57.9 months, tNME showed poorer 3-year recurrence-free survival (RFS) (56.0 % vs. 78.9 %, P=0.008) and 3-year overall survival (OS) (79.0 %vs. 87.7%, P=0.095) compared to NME. These were validated in the Korean multi-center validation cohort (3-year RFS: 55.3% vs. 74.5%, P=0.045), and TCGA cohort (3-year OS: 62.2% vs. 91.7%, P=0.071). Metagenomics exhibited a significantly lower proportion of carcinogenic genus including Fusobacterium, Bacteroides in normal of NME. There were significant differences in beta diversity between tumor and normal in NME, while no significant differences were noted in tNME, which suggests the feature of bacterial biofilm. PathSeq-based computational method of single-cell RNA sequencing revealed more proportion of infected cancer cells in tNME. EMP1 +epithelial cells were correlated with recurrence, and more proportion of this cluster, along with GZMK high CD8 T cells, inflammatory cancer-associated fibroblasts were noted in tumor of tNME, while more proportion of neutrophil was noted in normal of tNME.
Conclusions
The microenvironment of normal mucosa status could be a prognostic biomarker for CRC. The bacterial biofilm with weak intestinal barrier were related to tNME.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Bio & Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science & ICT (grant no. NRF2017M3A9A7050803.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2295P - Pan-cancer prevalence of MET fusions and clinical response to MET- targeted therapy
Presenter: Morana Vojnic
Session: Poster session 08
2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways
Presenter: Nicola Maurea
Session: Poster session 08
2297P - Gene co-expression networks capture the potential pathogenesis and progression of upper tract urothelial cancer
Presenter: Tingting Fu
Session: Poster session 08
2298P - Feasibility of ex vivo drug sensitivity testing in urothelial cancer: EVITA trial
Presenter: Mathijs Scholtes
Session: Poster session 08
2299P - Mebendazole enhances the anticancer effect of irinotecan and check-point inhibitor in vitro and in vivo
Presenter: Sharmineh Mansoori
Session: Poster session 08
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
2301P - Combining cancer patient spatial transcriptomics and bulk RNA-Seq data to drive insights into NSCLC
Presenter: Julia Bischof
Session: Poster session 08
2302P - Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays
Presenter: Md Marufur Rahman
Session: Poster session 08
2303P - Protein functional interpretation of gene variants observed in clinical next-generation sequencing (NGS) for pleural mesothelioma
Presenter: Ferdinando Cerciello
Session: Poster session 08
2304P - A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19 -17)
Presenter: Eun Joo Kang
Session: Poster session 08